Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2015 May;85:65-82. doi: 10.1016/j.addr.2014.11.004. Epub 2014 Nov 12.

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Author information

1
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
2
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia.
3
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Electronic address: colistin.polymyxin@gmail.com.

Abstract

One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.

KEYWORDS:

Antibiotics; Antifungals; Antivirals; Inhalation; Pharmacokinetics/pharmacodynamics; Safety

PMID:
25446140
PMCID:
PMC4429008
DOI:
10.1016/j.addr.2014.11.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center